Insurers eye pharma discounts beyond hepatitis C

Feb 2, 2015

The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs. Harvard Pilgrim Health Care’s chief medical officer, Dr. Michael Sherman, told Modern Healthcare a new class of cholesterol drugs will be “the next shock to the system,” prompting payers and drug companies to initiate similar rebate conversations.

[button title=”read more” link=”” target=”_blank” size=”” color=”” class=””]